Table 3
Age-specific predicted five-year relative survival ratios (RSRs) for women and percentage-unit superiority of estimates to corresponding estimates for men, by cancer, ages 15 to 99, Canada excluding Quebec, 2004-to-2008 periodNote 

Table 3
Age-specific predicted five-year relative survival ratios (RSRs) for women and percentage-unit superiority of estimates to corresponding estimates for men, by cancer, ages 15 to 99, Canada excluding Quebec, 2004-to-2008 period
Table summary
This table displays the results of Age-specific predicted five-year relative survival ratios (RSRs) for women and percentage-unit superiority of estimates to corresponding estimates for men. The information is grouped by Cancer (appearing as row headers), Age group (years), 15 to 44, 45 to 54, 55 to 64, 65 to 74, 75 to 99, Women (%), Women - Men, % units and 95% confidence interval, calculated using from and to units of measure (appearing as column headers).
Cancer Age group (years)
15 to 44 45 to 54 55 to 64 65 to 74 75 to 99
Women (%) Women - Men Women (%) Women - Men Women (%) Women - Men Women (%) Women - Men Women (%) Women - Men
% units 95% confidence interval % units 95% confidence interval % units 95% confidence interval % units 95% confidence interval % units 95% confidence interval
from to from to from to from to from to
All cancersNote  83.6 10.9 9.9 11.8 65.1 8.4 7.5 9.4 53.7 4.4 3.6 5.2 44.3 2.2 1.5 2.9 35.2 1.6 0.9 2.3
Case-mix-standardized 80.5 4.1 3.2 5.0 62.7 5.6 4.8 6.5 53.9 4.4 3.7 5.1 46.0 2.9 2.3 3.6 36.6 0.8 0.1 1.5
Oral cavity and pharynx 86.7 8.4 4.1 12.8 76.0 8.2 4.1 12.3 68.7 7.3 3.3 11.4 58.9 4.0 -0.4 8.4 56.5 4.6 -0.8 10.1
Esophagus 24.5 6.1 -12.2 24.3 21.0 4.8 -3.8 13.5 23.4 9.4 3.3 15.5 19.5 5.8 0.7 10.8 8.3 -1.7 -5.1 1.7
Stomach 39.2 8.3 -0.1 16.7 31.7 5.5 -0.2 11.3 30.8 5.2 0.6 9.8 30.7 5.8 1.9 9.8 19.4 0.3 -2.8 3.5
Colon 66.2 -3.0 -7.8 1.7 67.0 4.8 1.8 7.8 68.5 2.8 0.7 5.0 66.5 0.6 -1.3 2.5 59.3 1.6 -0.5 3.7
Rectum 72.9 6.6 0.5 12.8 72.7 7.9 4.3 11.5 71.2 2.7 -0.2 5.6 65.8 1.6 -1.2 4.5 57.9 3.6 0.3 6.9
Liver 55.5 18.3 2.0 34.7 28.8 2.9 -6.3 12.0 23.2 2.0 -4.8 8.7 16.9 1.0 -4.5 6.3 8.5 -1.3 -6.0 3.5
Pancreas 37.5 16.8 6.7 26.9 13.9 3.2 -0.9 7.3 8.9 1.2 -1.2 3.7 6.5 0.9 -1.0 2.7 4.8 0.5 -1.0 2.0
Larynx Note F: too unreliable to be published Note F: too unreliable to be published Note F: too unreliable to be published Note F: too unreliable to be published 69.8 1.1 -10.9 13.0 70.0 6.0 -2.4 14.5 55.8 -5.0 -13.3 3.4 54.9 -11.5 -23.6 0.7
Lung and bronchus 33.0 8.1 3.1 13.0 25.5 9.1 7.1 11.2 22.9 6.6 5.3 7.9 19.9 5.4 4.4 6.5 13.7 3.6 2.6 4.6
Skin melanoma 95.3 5.6 3.8 7.4 94.0 6.3 4.2 8.3 93.0 6.2 3.8 8.5 89.7 4.8 1.6 8.0 87.0 8.2 3.4 13.0
Bladder (including in situ) 81.3 -7.7 -14.6 -0.8 83.1 0.0 -4.4 4.3 79.6 -1.1 -4.3 2.2 73.9 -0.5 -3.7 2.6 55.8 -8.8 -12.1 -5.4
Kidney and renal pelvis 89.1 6.6 2.4 10.9 80.3 5.8 2.2 9.4 75.3 6.4 3.1 9.7 66.3 1.8 -1.9 5.5 51.2 -2.6 -7.2 2.0
Brain and other nervous system 64.5 8.0 3.3 12.7 36.3 9.3 3.9 14.6 18.1 4.9 1.0 8.9 12.8 3.6 0.2 7.0 7.5 2.4 -0.5 5.2
Thyroid 99.8 0.4 -0.4 1.2 99.9 3.7 1.8 5.6 98.5 3.2 0.5 6.0 97.7 10.9 5.5 16.2 87.7 6.7 -4.9 18.4
Hodgkin lymphoma 95.9 2.1 0.0 4.1 95.2 12.0 5.5 18.4 80.9 6.4 -3.7 16.4 67.8 12.8 -0.7 26.3 38.6 2.6 -12.8 18.0
Non-Hodgkin lymphoma 83.8 6.0 2.9 9.0 81.1 6.0 3.0 9.0 77.1 7.8 5.1 10.6 65.6 7.0 4.0 9.9 47.8 3.4 0.0 6.7
Multiple myeloma 64.6 -1.7 -15.4 12.0 66.7 8.4 0.9 16.0 50.8 -1.6 -7.4 4.3 37.2 -2.7 -7.7 2.3 25.9 2.4 -2.0 6.7
Leukemia 71.0 4.1 -0.5 8.7 70.9 -3.0 -7.5 1.5 67.4 -1.7 -5.6 2.2 59.8 3.5 -0.2 7.3 41.4 1.4 -2.3 5.1
OtherNote  and unknown 72.4 4.3 1.2 7.4 56.4 3.7 0.8 6.6 47.3 3.9 1.5 6.3 36.8 0.5 -1.5 2.6 25.4 -1.7 -3.4 0.1
Date modified: